Discover 1,705 paid clinical trials in Detroit, Michigan. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,705
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
for
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma,
Location: Detroit MI, Grosse Pointe Woods MI, Warren MI,
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: All
Age: 18+
Code: NCT04566328
Phase3, Recruiting
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
for
Hodgkin Lymphoma in Remission, Leukemia in Remission,
Location: Detroit MI, Akron OH, Cincinnati OH, Chicago IL,
Sponsor: Children's Oncology Group
Sex: All
Age: 0+
Code: NCT01790152
Recruiting
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
for
Mitral Valve Regurgitation
Location: Detroit MI, Ann Arbor MI, Cleveland OH, Grand Rapids MI,
Sponsor: Medtronic Cardiovascular
Sex: All
Age: 18+
Code: NCT03242642
Recruiting
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
for
Castration-Resistant Prostate Carcinoma,
Location: Detroit MI, Grosse Pointe Woods MI, Warren MI,
Sponsor: SWOG Cancer Research Network
Sex: Male
Age: 18+
Code: NCT06470243
Phase3, Recruiting
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
for
Malignancy
Location: Detroit MI, Grosse Pointe Woods MI, Warren MI,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 0+
Code: NCT04242095
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
for
Acute Coronary Syndrome
Location: Dearborn MI, Detroit MI, Mount Clemens MI, Ypsilanti MI,
Sponsor: DalCor Pharmaceuticals
Sex: All
Age: 45+
Code: NCT05918861
Phase3, Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations